Motor Cortex Plasticity Response to Theta-Burst Stimulation After Ketone Monoester Supplementation
- Conditions
- Healthy Young AdultNeurophysiology
- Registration Number
- NCT06799260
- Lead Sponsor
- Universiti Putra Malaysia
- Brief Summary
Transcranial magnetic stimulation is a medical device that can alter motor cortical (M1) excitability through the scalp via various protocols. Among these, intermittent- and continuous-theta burst stimulation (iTBS/cTBS) are increasingly used protocols to enhance or suppress M1 excitability, respectively, beyond stimulation. However, the poor reproducibility and high inter-individual variability in responses to TBS protocols are matters of concern. This study will explore whether ketone monoester supplementation can boost TBS efficacy via their mechanistic convergence on Brain-Derived Neurotrophic Factor (BDNF).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 40
- Healthy young adults (18-35 years old)
- Right-handed
- Fully vaccinated against COVID-19
- Subjects with contraindications to TMS based on the screening 13-item questionnaire for TMS safety
- Highly active subjects (athletes)
- Obese (BMI ≥ 30 kg/m2)
- Smokers
- Following intermittent fasting or ketogenic diet
- Long COVID-19
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method Motor evoked potential (MEP) Pre-TBS (baseline) and post-TBS at 0, 5, 10, 20, and 30 minutes. Peak-to-peak MEP amplitude elicited by single-pulse TMS over the left M1 representation of the first dorsal interosseous (FDI) muscle.
In each MEP measurement, 12 MEP readings will be collected, elicited by single-pulse TMS at an intensity of 120% resting motor threshold and separated by 15 seconds.
In each timepoint post-TBS, the mean value of MEPs (aka, conditioned MEPs) will be averaged and compared to pre-TBS (aka, baseline MEPs) using the following equation: (conditioned MEP amplitude/baseline MEP amplitude) × 100. A value of 90-110 represents no change, while values \< 90% represent suppression and \> 110% facilitation of the M1 plasticity following TBS.
- Secondary Outcome Measures
Name Time Method TMSens_Q questionnaire At 30 minutes post-TBS stimulation Self-reported side effects using the TMSens_Q questionnaire to evaluate the tolerability of the KME-TBS combination.
Corticospinal excitability indices Pre-KME supplementation and at 1 hour post-KME supplementation Resting motor threshold (RMT) followed by motor-evoked potential at 120% RMT intensity
Blood pressure Pre-supplementation, at 1 hour post-supplementation/pre-TBS stimulation, and serially thereafter every 3-5 minutes until 30 minutes post-TBS Systolic blood pressure (SBP), Diastolic Blood Pressure (DBP), and Mean Arterial Pressure (MAP) using fully automated oscillometric sphygmomanometer
Heart rate Pre-supplementation, at 1 hour post-supplementation/pre-TBS stimulation, and continuously thereafter for 30 minutes post-TBS Heart rate (bpm) using pulse oximeter
Blood glucose Pre-KME supplementation and at 30 minutes post-TBS stimulation On-site using a portable glucometer
BDNF genetic polymorphism At the baseline (pre-KME supplementation) BDNF rs6265 single nucleotide polymorphism
Blood beta-hydroxybutyrate Pre-KME supplementation and at 30 minutes post-TBS stimulation On-site using a portable glucometer
Serum brain-derived neurotrophic factor Pre-KME supplementation and at 30 minutes post-TBS stimulation Serum levels of mature brain-derived neurotrophic factor (mBDNF) and pro-BDNF isoforms
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Hospital Sultan Abdul Aziz Shah
🇲🇾Serdang, Selangor, Malaysia